Previous 10 | Next 10 |
Euro Tech Holdings Company ( CLWT ) +39% . SilverSun Technologies ( SSNT ) +28% . Aethlon Medical ( AEMD ) +19% CEO Chuck Fisher on Q1 2023 Results - Earnings Call Transcript. The Trade Desk ( TTD ) +16% Inc. 2023 Q2 - Results - Earnings C...
Celyad Oncology SA (CYAD) Q2 2022 Earnings Conference Call August 5, 2022 8:00 A.M. ET Company Participants Sara Zelkovic - Director, Communications and Investor Relations Michel Lussier - Interim Chief Executive Officer Charlie Morris - Chief Medical Officer ...
Celyad Oncology press release ( NASDAQ: CYAD ): 1H GAAP EPS of -€0.62. As of June 30, 2022, the Company had cash and cash equivalents of €14.4 million Shares -5% AH For further details see: Celyad Oncology GAAP EPS of -€0.62
Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM) In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold for the T-cell-inhibit...
InVivo Therapeutics Holdings ( NVIV ) +106% . GreenLight Biosciences ( GRNA ) +94% . NanoViricides ( NNVC ) +48% stock skyrockets 50% on start of drug development program for monkeypox. Exicure ( XCUR ) +39% . Global Blood Therapeuti...
Eliem Therapeutics ELYM -25% on report to discontinue development of lead asset as mid-stage pain trial fails . Mobile Global Esports (MGAM) -14% . Senti Biosciences ( SNTI ) -10% . Celyad Oncology ( CYAD ) -11% . Eos Energy Enterprises EOSE...
Gainers: Liberty TripAdvisor ( LTRPB ) +209% . Virax Biolabs Group ( VRAX ) +130% . Qurate Retail ( QRTEB ) +80% . MediaCo ( MDIA ) +67% . Nanobiotix ( NTX ) +47% . Aethlon Medical ( AEMD ) +46% . GeoVax ( ...
Gainers: Virax Biolabs ( VRAX ) +62% . Aethlon Medical ( AEMD ) +46% . GeoVax Labs ( GOVX ) +46% . Celyad Oncology ( CYAD ) +40% . Outset Medical ( OM ) +28% . Losers: Otonomy ( OTIC ) -77% . Kazia Therapeu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off Monday with a breakdown of the biggest pre-market stock movers traders will want to watch! We’ve got clinical trial data, public debuts, and more to...
Celyad Oncology ( NASDAQ: CYAD ) said the the U.S. Food and Drug Administration (FDA) a lifted a clinical hold on a phase 1b trial of its CAR T cell therapy CYAD-101, after the company made changes to the eligibility criteria for the trial. In March, the FDA placed a ...
News, Short Squeeze, Breakout and More Instantly...
Celyad SA Company Name:
CYAD Stock Symbol:
NASDAQ Market:
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price No...
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letterȁ...